CTMX (CytomX Therapeutics) Short Interest


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.28
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CTMX vs SMNR, AURA, OMER: Short Interest Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Short Interest falls into.


CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.28 is trading 1069.6% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Short Interest:
  • GF Value™: $0.28 vs. price of $3.28 (1069.6% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.28
Price
$0.28
GF Value